Signos, a metabolic health company, has secured $20M in Series B funding. Big names like Cheyenne Ventures and GV (Google Ventures) spearheaded the investment, joined by Dexcom Ventures and Samsung Next. The influx of capital is earmarked for team expansion, platform growth, and further research to underline Signos' commitment to revolutionizing metabolic health.